Thermo Fisher and Artificial, a developer of automation software, have entered into a strategic technology agreement to develop a software automation platform for Thermo Fisher’s standardised Covid-19 testing platform. The agreement is expected to scale Covid-19 testing volumes with improved software and robotics platforms. Artificial will allow its aLab Suite software to integrate with Thermo Scientific Momentum Workflow software and robotics hardware, while Thermo will utilise its experience to provide feedback to aLab Suite functionalities and capabilities.

Oxford BioDynamics has announced the launch of its EpiSwitch Covid-19 Severity Test (CST) in the US. The test is regarded as highly accurate in predicting severe illness caused by the SARS-CoV-2 virus. It requires a routine blood sample to identify high-risk individuals who may require hospitalisation and intensive care unit support. The test also enables care for individuals who cannot be vaccinated because they may be immunocompromised or due to other medical conditions.

The first antibody assay from Beckman Coulter, the Access SARS-CoV-2 IgG II, has received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA). The semi-quantitative assay measures the level of antibodies present in response to a previous SARS-CoV-2 infection. It also provides a qualitative and quantitative result of the antibodies in arbitrary units.